Nivalis Therapeutics Reports Second Quarter 2016 Financial Results
01 août 2016 16h05 HE
|
Nivalis Therapeutics, Inc.
Cavosonstat achieves significant phase 2 enrollment milestones during quarter BOULDER, Colo., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical-stage...
Nivalis Therapeutics Announces Completion of Enrollment in Phase 2 Study of N91115 for Treatment of Cystic Fibrosis
07 juil. 2016 07h00 HE
|
Nivalis Therapeutics, Inc.
- Study is Evaluating N91115 in Patients Homozygous for the F508del-CFTR Mutation and Being Treated with Orkambi™ - “Cavosonstat” Approved as the Unique Non-proprietary or Generic Name for N91115 -...
Nivalis Therapeutics to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
06 juil. 2016 16h05 HE
|
Nivalis Therapeutics, Inc.
BOULDER, Colo., July 06, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (“CF”), today...
Nivalis Therapeutics to Present at the JMP Securities Life Sciences Conference
15 juin 2016 07h00 HE
|
Nivalis Therapeutics, Inc.
BOULDER, Colo., June 15, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (“CF”), today...
Nivalis Therapeutics to Present at the Jefferies 2016 Healthcare Conference
01 juin 2016 07h00 HE
|
Nivalis Therapeutics, Inc.
BOULDER, Colo., June 01, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (“CF”), today...
Nivalis Therapeutics Announces First Patient Dosed in Second Phase 2 Study of N91115 for Treatment of Cystic Fibrosis
16 mai 2016 16h05 HE
|
Nivalis Therapeutics, Inc.
- Study to Evaluate N91115 in Patients Heterozygous for F508del-CFTR and a Gating Mutation - Data Expected in the First Half of 2017 BOULDER, Colo., May 16, 2016 (GLOBE NEWSWIRE) -- Nivalis...
Nivalis Therapeutics Reports First Quarter 2016 Financial Results
02 mai 2016 16h05 HE
|
Nivalis Therapeutics, Inc.
- Two Phase 2 Studies in Cystic Fibrosis Now EnrollingBOULDER, Colo., May 02, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical-stage pharmaceutical company focused...
Nivalis Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
22 avr. 2016 16h05 HE
|
Nivalis Therapeutics, Inc.
BOULDER, Colo., April 22, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (“CF”), today...
Nivalis Therapeutics Appoints David Rodman, MD as Chief Medical Officer and Executive Vice President of Discovery
18 avr. 2016 07h00 HE
|
Nivalis Therapeutics, Inc.
BOULDER, Colo., April 18, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (“CF”), today...
Nivalis Therapeutics Reaches 50 Percent Enrollment Milestone in Phase 2 Clinical Trial in Cystic Fibrosis
05 avr. 2016 08h00 HE
|
Nivalis Therapeutics, Inc.
BOULDER, Colo., April 05, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (“CF”), today...